{"type":"trials","record":{"id":41582,"source_id":"clinicaltrials-gov","external_id":"NCT06890026","title":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration","brief_summary":"Neovascular Age-Related Macular Degeneration (nAMD) is a one of the leading causes of irreversible vision loss among the elderly in developed countries. The implementation of anti-VEGF therapies in the last decades has significantly improved AMD management. Faricimab (Vabysmo®), a bispecific antibody targeting both Vascular Endothelial Growth Factor A (VEGF-A) and Angiopoietin-2 (Ang-2), offers enhanced disease control by both inhibiting angiogenesis and stabilizing blood vessels to prevent inflammation and leakage. Faricimab is thought to potentially reduce the frequency of injections compared to therapies targeting only VEGF-A. A key aspect of evaluating its efficacy is understanding the interval before the need for subsequent injections following the initial loading dose. Treatment with intravitreal anti-VEGF injections would typically start with three injections administered at four-weekly intervals, however faricimab is recommended to be started with four loading injections. Our department routinely initiates anti-VEGF therapy with 3 loading doses and then follows an observe-and-plan regimen. This routine was continued with faricimab injections as well despite the manufacturer's recommendation of 4 monthly loading doses. Determining the optimal interval for reinjection is crucial for reducing treatment burden and improving patient quality of life. This study aims to assess the durability of a loading dose of 3 faricimab injections, the need for a follow-up checkup at 4 weeks post-loading and functional outcomes post-loading in treatment-naive patients with neovascular age-related macular degeneration (nAMD),","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Rigshospitalet, Denmark","enrollment":742,"countries":["Denmark"],"start_date":"2024-11-15","completion_date":"2026-03-01","last_update_date":"2026-03-27","source_url":"https://clinicaltrials.gov/study/NCT06890026","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Rigshospitalet, Denmark","interventions":["Faricimab Injection [Vabysmo]"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Durability of the loadings dose with 3 faricimab injections — 01/NOV/2023 - 28/FEB/2025","Injection-free survival probabilities at prespecified time points (4-24 weeks post-loading in 2-weekly increments) — 01…","Change in best-corrected visual acuity (BCVA) following the loading phase with faricimab at 4 weeks. — 01/NOV/2023 - 28…"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-Related Macular Degeneration (nAMD)","Treatment-naïve","Faricimab Injection [Vabysmo]"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06890026","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-11-15 to 2026-03-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.837Z","intervention":["Faricimab Injection [Vabysmo]"],"participants":742,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Durability of the loadings dose with 3 faricimab injections — 01/NOV/2023 - 28/FEB/2025","Injection-free survival probabilities at prespecified time points (4-24 weeks post-loading in 2-weekly increments) — 01…","Change in best-corrected visual acuity (BCVA) following the loading phase with faricimab at 4 weeks. — 01/NOV/2023 - 28…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41582","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}